Literature DB >> 28456467

Dysfunctional T cell metabolism in the tumor microenvironment.

Kathryn E Beckermann1, Stephanie O Dudzinski2, Jeffrey C Rathmell3.   

Abstract

Metabolic and signaling pathways are integrated to determine T cell fate and function. As stimulated T cells gain distinct effector functions, specific metabolic programs and demands are also adopted. These changes are essential for T cell effector function, and alterations or dysregulation of metabolic pathways can modulate T cell function. One physiological setting that impacts T cell metabolism is the tumor microenvironment. The metabolism of cancer cells themselves can limit nutrients and accumulate waste products. In addition to the expression of inhibitory ligands that directly modify T cell physiology, T cell metabolism may be strongly inhibited in the tumor microenvironment. This suppression of T cell metabolism may inhibit effector T cell activity while promoting suppressive regulatory T cells, and act as a barrier to effective immunotherapies. A thorough understanding of the effect of the tumor microenvironment on the immune system will support the continued improvement of immune based therapies for cancer patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glycolysis; Immunotherapy; Mitochondria; Oxidative phosphorylation; T-cell

Mesh:

Year:  2017        PMID: 28456467      PMCID: PMC5710836          DOI: 10.1016/j.cytogfr.2017.04.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  85 in total

1.  The CD28 signaling pathway regulates glucose metabolism.

Authors:  Kenneth A Frauwirth; James L Riley; Marian H Harris; Richard V Parry; Jeffrey C Rathmell; David R Plas; Rebecca L Elstrom; Carl H June; Craig B Thompson
Journal:  Immunity       Date:  2002-06       Impact factor: 31.745

2.  Survival of effector CD8+ T cells during influenza infection is dependent on autophagy.

Authors:  Katrin Schlie; Ashley Westerback; Lindsay DeVorkin; Luke R Hughson; Jillian M Brandon; Sarah MacPherson; Izabelle Gadawski; Katelin N Townsend; Vincent I Poon; Mary A Elrick; Helene C F Côté; Ninan Abraham; E John Wherry; Noboru Mizushima; Julian J Lum
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

3.  The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction.

Authors:  Nicole E Scharping; Ashley V Menk; Rebecca S Moreci; Ryan D Whetstone; Rebekah E Dadey; Simon C Watkins; Robert L Ferris; Greg M Delgoffe
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

4.  Differential PI3Kδ Signaling in CD4+ T-cell Subsets Enables Selective Targeting of T Regulatory Cells to Enhance Cancer Immunotherapy.

Authors:  Shamim Ahmad; Rasha Abu-Eid; Rajeev Shrimali; Mason Webb; Vivek Verma; Atbin Doroodchi; Zuzana Berrong; Raed Samara; Paulo C Rodriguez; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

5.  The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo.

Authors:  Julianna Blagih; François Coulombe; Emma E Vincent; Fanny Dupuy; Gabriela Galicia-Vázquez; Ekaterina Yurchenko; Thomas C Raissi; Gerritje J W van der Windt; Benoit Viollet; Erika L Pearce; Jerry Pelletier; Ciriaco A Piccirillo; Connie M Krawczyk; Maziar Divangahi; Russell G Jones
Journal:  Immunity       Date:  2015-01-02       Impact factor: 31.745

Review 6.  Metabolism of inflammation limited by AMPK and pseudo-starvation.

Authors:  Luke A J O'Neill; D Grahame Hardie
Journal:  Nature       Date:  2013-01-17       Impact factor: 49.962

7.  Foxp3-mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells.

Authors:  Samik Basu; Britany Hubbard; Ethan M Shevach
Journal:  J Leukoc Biol       Date:  2014-12-09       Impact factor: 4.962

8.  Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming.

Authors:  Michael D Buck; David O'Sullivan; Ramon I Klein Geltink; Jonathan D Curtis; Chih-Hao Chang; David E Sanin; Jing Qiu; Oliver Kretz; Daniel Braas; Gerritje J W van der Windt; Qiongyu Chen; Stanley Ching-Cheng Huang; Christina M O'Neill; Brian T Edelson; Edward J Pearce; Hiromi Sesaki; Tobias B Huber; Angelika S Rambold; Erika L Pearce
Journal:  Cell       Date:  2016-06-09       Impact factor: 41.582

Review 9.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

Authors:  David H Munn; Andrew L Mellor
Journal:  Trends Immunol       Date:  2016-01-31       Impact factor: 16.687

10.  TSC1 regulates the balance between effector and regulatory T cells.

Authors:  Yoon Park; Hyung-Seung Jin; Justine Lopez; Chris Elly; Gisen Kim; Masako Murai; Mitchell Kronenberg; Yun-Cai Liu
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

View more
  37 in total

1.  Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Authors:  Tsadik Habtetsion; Zhi-Chun Ding; Wenhu Pi; Tao Li; Chunwan Lu; Tingting Chen; Caixia Xi; Helena Spartz; Kebin Liu; Zhonglin Hao; Nahid Mivechi; Yuqing Huo; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Cell Metab       Date:  2018-06-07       Impact factor: 27.287

Review 2.  Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Authors:  Mahmoud Chaker; Audrey Minden; Suzie Chen; Robert H Weiss; Eduardo N Chini; Amit Mahipal; Asfar S Azmi
Journal:  Expert Opin Ther Targets       Date:  2017-12-10       Impact factor: 6.902

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

4.  P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy.

Authors:  Kelsey M Wanhainen; Changwei Peng; Maggie H Zhou; Bruna de Gois Macedo; Stephen O'Flanagan; Tingyuan Yang; Ameeta Kelekar; Brandon J Burbach; Henrique Borges da Silva; Stephen C Jameson
Journal:  Cancer Immunol Res       Date:  2022-07-01       Impact factor: 12.020

5.  PDK4 Constitutes a Novel Prognostic Biomarker and Therapeutic Target in Gastric Cancer.

Authors:  Zimu Zhang; Shiyuan Han; Siwen Ouyang; Ziyang Zeng; Zhen Liu; Juan Sun; Weiming Kang
Journal:  Diagnostics (Basel)       Date:  2022-04-27

Review 6.  Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.

Authors:  Guangna Liu; Wei Rui; Xueqiang Zhao; Xin Lin
Journal:  Cell Mol Immunol       Date:  2021-03-30       Impact factor: 11.530

Review 7.  Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction.

Authors:  Natalia Di Ianni; Silvia Musio; Serena Pellegatta
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

Review 8.  Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.

Authors:  Soumaya Kouidhi; Farhat Ben Ayed; Amel Benammar Elgaaied
Journal:  Front Immunol       Date:  2018-02-23       Impact factor: 7.561

9.  Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.

Authors:  Joseph Barbi; Santosh K Patnaik; Sarabjot Pabla; Robert Zollo; Randall J Smith; Stephanie N Sass; Aravind Srinivasan; Cara Petrucci; Robert Seager; Jeffrey Conroy; Eric Kannisto; Xialong Wang; Shrunjal Shah; Rohit Gosain; Kris Attwood; Charles Roche; Sai Yendamuri
Journal:  J Thorac Oncol       Date:  2021-05-25       Impact factor: 20.121

Review 10.  Stress relief for cancer immunotherapy: implications for the ER stress response in tumor immunity.

Authors:  Alex M Andrews; Megan D Tennant; Jessica E Thaxton
Journal:  Cancer Immunol Immunother       Date:  2020-10-26       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.